Intuitive Surgical, Inc. logo

Intuitive Surgical, Inc. (ISRG)

Market Open
4 Jun, 13:37
NASDAQ (NGS) NASDAQ (NGS)
$
414. 89
+7.6
+1.866%
$
150.03B Market Cap
76.32 P/E Ratio
- Div Yield
127,712 Volume
5.59 Eps
$ 407.29
Previous Close
Add Transaction
Day Range
412.69 418
Year Range
396.68 603.88
Want to track ISRG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ISRG Stock Forms Golden Crossover: Will the Uptrend Continue?

ISRG Stock Forms Golden Crossover: Will the Uptrend Continue?

Intuitive Surgical's golden crossover arrives amid surging procedures and rapid dV5 adoption, raising the stakes for its bullish momentum.

Zacks | 5 months ago
Intuitive Surgical: Is The Smart Money Moving In?

Intuitive Surgical: Is The Smart Money Moving In?

Intuitive Surgical (ISRG) stock may represent a worthwhile investment at present. Why? Because you receive high margins – indicative of pricing power and cash generation capability – at a discounted price.

Forbes | 6 months ago
Is It Time To Buy Intuitive Surgical Stock?

Is It Time To Buy Intuitive Surgical Stock?

Intuitive Surgical (ISRG) stock may represent a worthwhile investment at present. Why? Because you receive high margins – indicative of pricing power and cash generation capability – at a discounted price.

Forbes | 6 months ago
Margins Face Tariff Pressure: Is ISRG's Profitability at Risk?

Margins Face Tariff Pressure: Is ISRG's Profitability at Risk?

Intuitive Surgical's strong growth contrasts with tariff-driven margin pressure, raising questions about its ability to hold gross margins near 67%.

Zacks | 6 months ago
Here's Why Intuitive Surgical, Inc. (ISRG) Fell More Than Broader Market

Here's Why Intuitive Surgical, Inc. (ISRG) Fell More Than Broader Market

In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $567.37, denoting a -1.07% move from the preceding trading day.

Zacks | 6 months ago
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know

Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 6 months ago
Can Intuitive Surgical Still Be A Good Buy?

Can Intuitive Surgical Still Be A Good Buy?

Intuitive Surgical (ISRG) stock may be a solid investment at this time. Why? Because you're getting high margins – indicative of pricing power and cash generation capability – for a discounted price.

Forbes | 6 months ago
From Hospitals to ASCs: Will Refurbished Xi Systems Broaden ISRG's Reach?

From Hospitals to ASCs: Will Refurbished Xi Systems Broaden ISRG's Reach?

ISRG leverages refurbished Xi systems to reach cost-sensitive markets and expand access beyond hospitals.

Zacks | 6 months ago
ISRG vs. MDT: A High-Tech Robotics Faceoff in the Race for Leadership

ISRG vs. MDT: A High-Tech Robotics Faceoff in the Race for Leadership

Intuitive Surgical's robotics surge and Medtronic's broad innovation push set the stage for a high-tech showdown in next-gen minimally invasive care.

Zacks | 6 months ago
Why Is Intuitive Surgical (ISRG) Up 7.1% Since Last Earnings Report?

Why Is Intuitive Surgical (ISRG) Up 7.1% Since Last Earnings Report?

Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock?

Zacks | 6 months ago
Intuitive Surgical, Inc. (ISRG) Recently Broke Out Above the 20-Day Moving Average

Intuitive Surgical, Inc. (ISRG) Recently Broke Out Above the 20-Day Moving Average

After reaching an important support level, Intuitive Surgical, Inc. (ISRG) could be a good stock pick from a technical perspective. ISRG surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

Zacks | 6 months ago
Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?

Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?

Intuitive Surgical's Ion platform represents robust growth potential with strong procedure growth. Clinical trial data demonstrate superiority in diagnostic yield.

Zacks | 6 months ago
Loading...
Load More